Reuters logo
BRIEF-Matinas Biopharma retains JSB Partners to pursue strategic options for MAT9001
September 12, 2017 / 11:38 AM / 3 months ago

BRIEF-Matinas Biopharma retains JSB Partners to pursue strategic options for MAT9001

Sept 12 (Reuters) - Matinas Biopharma Holdings Inc:

* Matinas Biopharma retains JSB Partners to pursue strategic options for MAT9001

* Matinas Biopharma Holdings Inc - ‍retained JSB Partners to identify a partner for company’s legacy cardiovascular product candidate, MAT9001​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below